{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T18:44:50Z","timestamp":1649184290689},"reference-count":26,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1536\/ihj.16-220","type":"journal-article","created":{"date-parts":[[2017,5,7]],"date-time":"2017-05-07T22:11:02Z","timestamp":1494195062000},"page":"385-392","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Tolvaptan With or Without the Pre-Administration of Renin-Angiotensin System Blockers in Hospitalized Patients With Acute Decompensated Heart Failure"],"prefix":"10.1536","volume":"58","author":[{"given":"Sen","family":"Adachi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Shiga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaaki","family":"Arimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Morii","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kuwano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Morito","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanta","family":"Fujimi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Yahiro","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keijiro","family":"Saku","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","unstructured":"1. Hunt SA, Abraham WT, Chin MH, <i>et al<\/i>; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112; e154-235."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.","DOI":"10.1053\/euhj.2001.2783"},{"key":"3","unstructured":"3. Redfield MM. Heart failure--an epidemic of uncertain proportions N Engl J Med 2002; 347: 1442-4."},{"key":"4","unstructured":"4. Writing Committee Members, Yancy CW, Jessup M, Bozkurt B, <i>et al<\/i>; American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-327."},{"key":"5","unstructured":"5. McMurray JJ, Adamopoulos S, Anker SD, <i>et al<\/i>; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 2003; 32: 459-81. (Review)","DOI":"10.1016\/S0889-8529(03)00004-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J 2014; 78: 844-52.","DOI":"10.1253\/circj.CJ-66-0093"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gheorghiade M, Niazi I, Ouyang J, <i>et al<\/i>; Tolvaptan Investigators. Vasopression V2-receptor blockade with tolvaptan in patients with chronic heart failure: results form a doubleblind, randomized trial. Circulation 2003; 107: 2690-6.","DOI":"10.1161\/01.CIR.0000070422.41439.04"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Konstam MA, Gheorghiade M, Burnett JC Jr, <i>et al<\/i>; Efficacy of Vasopression Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.","DOI":"10.1001\/jama.297.12.1319"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Udelson JE, McGrew FA, Flores E, <i>et al<\/i>. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151-9.","DOI":"10.1016\/j.jacc.2007.01.091"},{"key":"11","unstructured":"11. Ogawa H, Ajioka M, Ishii H, <i>et al<\/i>. Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure. Nagoya J Med Sci 2015; 77: 355-62."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Suzuki S, Yoshihisa A, Yamaki T, <i>et al<\/i>; AVCMA investigators. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure. Int Heart J 2015; 56: 213-8.","DOI":"10.1536\/ihj.14-248"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kimura M, Nawata K, Kinoshita O, <i>et al<\/i>. Successful treatment of intractable fluid retention using tolvaptan after treatment for postoperative mediastinitis in a patient with a left ventricular assist device. Int Heart J 2015; 56: 574-7.","DOI":"10.1536\/ihj.14-412"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Uemura Y, Shibata R, Takemoto K, <i>et al<\/i>. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 2016; 31: 1643-9.","DOI":"10.1007\/s00380-015-0775-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shimamoto K, Ando K, Fujita T, <i>et al<\/i>; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253-390.","DOI":"10.1038\/hr.2014.20"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Robles NR, Romero B, de Vinuesa EG, S\u00e1nchez-Casado E, Cubero JJ. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32: 192-7.","DOI":"10.3109\/08860220903541135"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Perico N, Zoja C, Corna D, <i>et al<\/i>. V1\/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009; 76: 960-7.","DOI":"10.1038\/ki.2009.267"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Gonzalez AA, Cifuentes-Araneda F, Ibaceta-Gonzalez C, <i>et al<\/i>. Vasopressin\/V2 receptor stimulates renin synthesis in the collecting duct. Am J Physiol Renal Physiol 2016; 310: F284-93.","DOI":"10.1152\/ajprenal.00360.2015"},{"key":"19","unstructured":"19. Nodari S, Jao GT, Chiong JR. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients. Int J Nephrol Renovasc Dis 2010; 3: 51-60."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther 2011; 25: S67-76.","DOI":"10.1007\/s10557-011-6350-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol 2013; 17: 834-8.","DOI":"10.1007\/s10157-013-0788-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Imamura T, Kinugawa K, Shiga T, <i>et al<\/i>. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients-association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.","DOI":"10.1253\/circj.CJ-12-0971"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tanaka A, Katsuno T, Ozaki T, <i>et al<\/i>. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol 2015; 70: 217-23.","DOI":"10.1080\/AC.70.2.3073514"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190-5.","DOI":"10.1056\/NEJM199511023331806"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Butler J, Forman DE, Abraham WT, <i>et al<\/i>. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331-8.","DOI":"10.1016\/j.ahj.2003.08.012"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Gheorghiade M, Gattis WA, O\u2019Connor CM, <i>et al<\/i>; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.","DOI":"10.1001\/jama.291.16.1963"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/3\/58_16-220\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T17:43:01Z","timestamp":1569260581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/3\/58_16-220\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.16-220","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}